https://www.gracetx.com/ https://www.gracetx.com/about-us https://www.gracetx.com/about-us/management-team https://www.gracetx.com/about-us/board-of-directors https://www.gracetx.com/about-us/scientific-advisory-board https://www.gracetx.com/gtx-104 https://www.gracetx.com/gtx-104/strive-on-trial-summary https://www.gracetx.com/gtx-104/publications https://www.gracetx.com/our-pipeline https://www.gracetx.com/investors https://www.gracetx.com/investors/news-events https://www.gracetx.com/investors/news-events/press-releases https://www.gracetx.com/investors/news-events/ir-calendar https://www.gracetx.com/investors/news-events/email-alerts https://www.gracetx.com/investors/company-information https://www.gracetx.com/investors/company-information/presentations https://www.gracetx.com/investors/company-information/contacts https://www.gracetx.com/investors/company-information/faq https://www.gracetx.com/investors/financial-results https://www.gracetx.com/investors/stock-data/quote-chart https://www.gracetx.com/investors/stock-data/historical-data https://www.gracetx.com/investors/stock-data/analyst-coverage https://www.gracetx.com/investors/sec-filings https://www.gracetx.com/investors/sec-filings/all-sec-filings https://www.gracetx.com/investors/sec-filings/annual-reports https://www.gracetx.com/investors/sec-filings/section-16-filings https://www.gracetx.com/investors/sec-filings/tax-notifications https://www.gracetx.com/investors/corporate-governance/management-team https://www.gracetx.com/investors/corporate-governance/board-of-directors https://www.gracetx.com/investors/corporate-governance/board-committees https://www.gracetx.com/investors/corporate-governance/governance-documents https://www.gracetx.com/contact-us https://www.gracetx.com/investors/news-events/press-releases/detail/308/grace-therapeutics-to-participate-in-the-h-c-wainright-28th-annual-global-investment-conference https://www.gracetx.com/investors/news-events/press-releases/detail/307/grace-therapeutics-announces-first-quarter-2027-financial-results-provides-business-update https://www.gracetx.com/investors/news-events/press-releases/detail/306/grace-therapeutics-announces-10-million-private-placement https://www.gracetx.com/investors/news-events/press-releases/detail/305/grace-therapeutics-announces-receipt-of-type-a-meeting-minutes-from-u-s-food-and-drug-administration https://www.gracetx.com/investors/news-events/press-releases/detail/304/grace-therapeutics-announces-2026-fiscal-year-end-financial-results-provides-business-update https://www.gracetx.com/investors/news-events/press-releases/detail/303/grace-therapeutics-provides-regulatory-update-on-new-drug-application-for-gtx-104 https://www.gracetx.com/investors/news-events/press-releases/detail/302/grace-therapeutics-announces-abstract-highlighting-strive-on-phase-3-trial-results-accepted-for-presentation-at-aan-2026 https://www.gracetx.com/investors/news-events/press-releases/detail/301/grace-therapeutics-to-present-data-on-the-unmet-medical-needs-and-potential-benefits-of-gtx-104-in-the-treatment-of-asah-at-upcoming-medical-conferences https://www.gracetx.com/investors/news-events/press-releases/detail/300/grace-therapeutics-to-participate-in-the-td-cowen-46th-annual-health-care-conference https://www.gracetx.com/investors/news-events/press-releases/detail/299/grace-therapeutics-announces-third-quarter-2026-financial-results-provides-business-update https://www.gracetx.com/investors/news-events/press-releases/detail/298/grace-therapeutics-to-participate-in-16th-annual-craig-hallum-alpha-select-conference https://www.gracetx.com/investors/news-events/press-releases/detail/297/grace-therapeutics-announces-second-quarter-2026-financial-results-provides-business-update https://www.gracetx.com/investors/news-events/press-releases/detail/296/grace-therapeutics-announces-abstract-accepted-for-presentation-at-society-of-vascular-and-interventional-neurology-annual-meeting https://www.gracetx.com/investors/news-events/press-releases/detail/295/grace-therapeutics-secures-approximately-4-0-million-through-common-warrant-exercises-following-acceptance-of-new-drug-application-for-gtx-104-for-formal-fda-review https://www.gracetx.com/investors/news-events/press-releases/detail/294/grace-therapeutics-pivotal-phase-3-strive-on-safety-trial-presented-at-2025-neurocritical-care-annual-meeting https://www.gracetx.com/investors/news-events/press-releases/detail/293/grace-therapeutics-granted-sixth-u-s-patent-covering-i-v-dosing-regimen-for-gtx-104 https://www.gracetx.com/investors/news-events/press-releases/detail/292/grace-therapeutics-announces-presentation-at-the-h-c-wainwright-27th-annual-global-investment-conference https://www.gracetx.com/investors/news-events/press-releases/detail/291/grace-therapeutics-announces-u-s-food-and-drug-administration-acceptance-for-review-of-new-drug-application-for-gtx-104 https://www.gracetx.com/investors/news-events/press-releases/detail/290/grace-therapeutics-announces-first-quarter-2026-financial-resultsprovides-business-update https://www.gracetx.com/investors/news-events/press-releases/detail/289/grace-therapeutics-announces-submission-of-new-drug-application-to-u-s-food-and-drug-administration-for-gtx-104 https://www.gracetx.com/investors/news-events/press-releases/detail/288/grace-therapeutics-announces-2025-fiscal-year-end-results-provides-business-update https://www.gracetx.com/investors/news-events/press-releases/detail/287/grace-therapeutics-to-participate-in-the-2025-bio-international-conference https://www.gracetx.com/investors/news-events/press-releases/detail/286/grace-therapeutics-announces-alignment-with-the-fda-supporting-the-planned-nda-submission-for-gtx-104 https://www.gracetx.com/investors/news-events/press-releases/detail/285/grace-therapeutics-to-participate-in-the-td-cowen-45th-annual-health-care-conference https://www.gracetx.com/investors/news-events/press-releases/detail/284/grace-therapeutics-announces-third-fiscal-quarter-2025financial-results-provides-business-update https://www.gracetx.com/investors/news-events/press-releases/detail/283/grace-therapeutics-announces-private-placement-financingof-up-to-30-million https://www.gracetx.com/investors/news-events/press-releases/detail/282/grace-therapeutics-announces-results-from-pivotal-phase-3-strive-on-safety-trial-of-gtx-104-in-asah https://www.gracetx.com/investors/news-events/press-releases/detail/281/grace-therapeutics-to-participate-in-upcoming-investor-events-january-2025 https://www.gracetx.com/investors/news-events/press-releases/detail/280/grace-therapeutics-to-exhibit-at-the-american-society-of-health-system-pharmacists-conference https://www.gracetx.com/investors/news-events/press-releases/detail/279/grace-therapeutics-announces-second-fiscal-quarter-2025-financial-results-provides-business-update https://www.gracetx.com/investors/news-events/press-releases/detail/278/grace-therapeutics-to-host-virtual-kol-event-on-gtx-104-in-aneurysmal-subarachnoid-hemorrhage-on-november-20-2024 https://www.gracetx.com/investors/news-events/press-releases/detail/277/acasti-announces-corporate-name-change-to-grace-therapeutics-inc https://www.gracetx.com/investors/news-events/press-releases/detail/276/acasti-announces-completion-of-patient-enrollment-in-pivotal-phase-3-strive-on-safety-trial-of-gtx-104 https://www.gracetx.com/investors/news-events/press-releases/detail/275/acasti-to-present-at-the-life-sciences-investor-forum https://www.gracetx.com/investors/news-events/press-releases/detail/274/acasti-to-participate-in-the-h-c-wainwright-26th-annual-global-investment-conference https://www.gracetx.com/investors/news-events/press-releases/detail/273/acasti-announces-first-fiscal-quarter-2025-financial-results-provides-business-update https://www.gracetx.com/investors/news-events/press-releases/detail/272/acasti-announces-achievement-of-50-enrollment-in-pivotal-phase-3-strive-on-safety-trial https://www.gracetx.com/investors/news-events/press-releases/detail/271/acasti-announces-year-end-2024-financial-results-provides-business-update https://www.gracetx.com/investors/news-events/press-releases/detail/270/acasti-pharma-to-attend-bio-international-convention-2024 https://www.gracetx.com/investors/news-events/press-releases/detail/269/acasti-announces-third-fiscal-quarter-2024-financial-results-and-business-highlights https://www.gracetx.com/investors/news-events/press-releases/detail/268/acasti-announces-poster-detailing-its-gtx-104-strive-on-trial https://www.gracetx.com/investors/news-events/press-releases/detail/267/acasti-to-participate-in-upcoming-san-francisco-investor-conferences-in-january-2024 https://www.gracetx.com/investors/news-events/press-releases/detail/266/acasti-announces-second-quarter-2024-financial-results-and-business-highlights https://www.gracetx.com/investors/news-events/press-releases/detail/265/acasti-announces-dosing-of-first-patient-in-gtx-104-strive-on-trial https://www.gracetx.com/investors/news-events/press-releases/detail/264/acasti-pharma-to-host-kol-event-on-gtx-104-a-potential-new-treatment-standard-for-rare-and-life-threatening-aneurysmal-subarachnoid-hemorrhage-asah https://www.gracetx.com/investors/news-events/press-releases/detail/263/acasti-announces-7-5-million-private-placement-equity-financing https://www.gracetx.com/investors/news-events/press-releases/detail/262/acasti-to-participate-in-the-h-c-wainwright-global-investment-conference https://www.gracetx.com/investors/news-events/press-releases/detail/261/acasti-announces-first-quarter-2024-financial-results-and-business-highlights https://www.gracetx.com/investors/news-events/press-releases/detail/260/acasti-to-present-gtx-104-pharmacokinetic-comparison-data-at-neurocritical-care-annual-meeting https://www.gracetx.com/investors/news-events/press-releases/detail/259/acasti-announces-wuxi-clinical-as-cro-to-conduct-strive-on-pivotal-phase-3-safety-trial-for-gtx-104-in-asah-patients https://www.gracetx.com/investors/news-events/press-releases/detail/258/acasti-pharma-announces-1-for-6-reverse-stock-split https://www.gracetx.com/investors/news-events/press-releases/detail/257/acasti-announces-alignment-with-fda-on-gtx-104-pivotal-phase-3-safety-trial-protocol-and-confirms-planned-initiation-of-strive-on-in-asah-patients-in-calendar-q4-2023 https://www.gracetx.com/investors/news-events/press-releases/detail/256/acasti-pharma-reports-fiscal-year-2023-operational-results https://www.gracetx.com/investors/news-events/press-releases/detail/255/acasti-announces-appointment-of-new-scientific-advisory-board-members https://www.gracetx.com/investors/news-events/press-releases/detail/254/acasti-to-participate-in-the-lytham-partners-spring-2023-investor-conference https://www.gracetx.com/investors/news-events/press-releases/detail/253/acasti-successfully-submits-pivotal-gtx-104-phase-3-safety-study-protocol-with-fda-and-implements-strategic-realignment-plan-that-extends-projected-cash-runway-through-calendar-q2-2025 https://www.gracetx.com/investors/news-events/press-releases/detail/252/acasti-to-proceed-with-phase-3-clinical-safety-study-for-gtx-104-following-fda-feedback-and-upon-approval-of-the-full-study-protocol-to-be-submitted-to-the-ind https://www.gracetx.com/investors/news-events/press-releases/detail/251/acasti-announces-appointment-of-prashant-kohli-as-ceo https://www.gracetx.com/investors/news-events/press-releases/detail/250/acasti-pharma-inc-announces-the-resignation-of-a-director https://www.gracetx.com/investors/news-events/press-releases/detail/249/acasti-pharma-inc-centralizes-marketplace-for-shares-on-the-nasdaq-with-voluntary-delisting-from-tsx-venture-exchange https://www.gracetx.com/investors/news-events/press-releases/detail/248/acasti-pharma-to-participate-in-oppenheimer-33rd-annual-healthcare-conference https://www.gracetx.com/investors/news-events/press-releases/detail/247/acasti-pharma-recognizes-rare-disease-day https://www.gracetx.com/investors/news-events/press-releases/detail/246/acasti-pharma-reports-third-quarter-2023-operational-results https://www.gracetx.com/investors/news-events/press-releases/detail/245/acasti-pharma-to-report-third-quarter-2023-financial-results-on-tuesday-february-14-2023 https://www.gracetx.com/investors/news-events/press-releases/detail/244/acasti-receives-extension-to-regain-compliance-with-nasdaq-minimum-bid-price-rule https://www.gracetx.com/investors/news-events/press-releases/detail/243/acasti-pharma-to-present-at-lytham-partners-investor-select-conference-on-january-31 https://www.gracetx.com/investors/news-events/press-releases/detail/242/acasti-pharma-to-present-at-sidoti-virtual-investor-conference-on-january-18 https://www.gracetx.com/investors/news-events/press-releases/detail/241/acasti-to-host-conference-call-on-tuesday-january-10-2023-to-discuss-results-from-recent-phase-1-pk-studies-for-gtx-101-and-gtx-102-that-met-all-outcome-measures https://www.gracetx.com/investors/news-events/press-releases/detail/240/acasti-announces-preliminary-topline-results-met-all-outcome-measures-in-the-pharmacokinetic-bridging-study-for-gtx-102-the-companys-drug-candidate-for-the-treatment-of-ataxia-telangiectasia https://www.gracetx.com/investors/news-events/press-releases/detail/239/acasti-pharma-announces-preliminary-topline-results-met-all-primary-outcome-measures-in-the-single-dose-pharmacokinetic-study-for-gtx-101-the-companys-drug-candidate-for-the-treatment-of-postherpetic-neuralgia-phn https://www.gracetx.com/investors/news-events/press-releases/detail/238/acasti-pharma-reports-second-quarter-2023-operational-results https://www.gracetx.com/investors/news-events/press-releases/detail/237/acasti-pharma-to-present-at-q4-investor-summit https://www.gracetx.com/investors/news-events/press-releases/detail/236/acasti-pharma-to-report-second-quarter-2023-financial-results-on-monday-november-14-2022 https://www.gracetx.com/investors/news-events/press-releases/detail/235/acasti-announces-court-dismissal-of-stockholder-litigation https://www.gracetx.com/investors/news-events/press-releases/detail/234/acasti-announces-voting-results-from-2022-annual-and-special-meeting-of-shareholders https://www.gracetx.com/investors/news-events/press-releases/detail/233/acasti-pharma-to-participate-in-the-lytham-partners-fall-2022-investor-conference https://www.gracetx.com/investors/news-events/press-releases/detail/232/acasti-pharma-announces-initiation-of-pharmacokinetic-study-for-gtx-102-the-companys-drug-candidate-for-the-treatment-of-ataxia-telangiectasia https://www.gracetx.com/investors/news-events/press-releases/detail/231/acasti-pharma-to-participate-at-the-h-c-wainwright-24th-annual-global-investment-conference https://www.gracetx.com/investors/news-events/press-releases/detail/230/acasti-pharma-reports-first-quarter-2023-operational-results https://www.gracetx.com/investors/news-events/press-releases/detail/229/acasti-pharma-to-report-first-quarter-2023-financial-results-on-thursday-august-11-2022 https://www.gracetx.com/investors/news-events/press-releases/detail/228/acasti-pharma-announces-initiation-of-pharmacokinetic-study-for-gtx-101-the-companys-drug-candidate-for-the-treatment-of-postherpetic-neuralgia https://www.gracetx.com/investors/news-events/press-releases/detail/227/acasti-pharma-announces-annual-grants-of-performance-stock-options https://www.gracetx.com/investors/news-events/press-releases/detail/226/acasti-pharma-reports-fiscal-year-2022-operational-results https://www.gracetx.com/investors/news-events/press-releases/detail/225/acasti-pharma-schedules-fiscal-year-2022-business-update-conference-call https://www.gracetx.com/investors/news-events/press-releases/detail/224/acasti-pharma-announces-the-issuance-of-additional-patents-for-gtx-104-and-gtx-101 https://www.gracetx.com/investors/news-events/press-releases/detail/223/acasti-pharma-inc-retains-lytham-partners-to-lead-strategic-investor-relations-and-shareholder-communication-program https://www.gracetx.com/investors/news-events/press-releases/detail/222/acasti-pharma-announces-positive-results-for-pharmacokinetic-bridging-study-with-intravenous-gtx-104-meeting-all-endpoints https://www.gracetx.com/investors/news-events/press-releases/detail/221/acasti-pharma-ceo-to-present-at-microcap-rodeos-spring-into-action-best-ideas-virtual-conference-on-may-18th https://www.gracetx.com/investors/news-events/press-releases/detail/219/acasti-pharma-to-present-at-the-b-riley-securities-2022-virtual-neuro-ophthalmology-conference-on-april-28th https://www.gracetx.com/investors/news-events/press-releases/detail/218/acasti-pharma-appoints-healthcare-industry-leader-michael-l-derby-to-its-board-of-directors https://www.gracetx.com/investors/news-events/press-releases/detail/217/acasti-pharma-announces-patents-for-gtx-104-in-europe-gtx-102-in-the-u-s-and-gtx-101-in-japan https://www.gracetx.com/investors/news-events/press-releases/detail/216/acasti-pharma-celebrates-rare-disease-day https://www.gracetx.com/investors/news-events/press-releases/detail/215/acasti-pharma-provides-business-update-for-the-third-quarter-of-fiscal-2022 https://www.gracetx.com/investors/news-events/press-releases/detail/214/acasti-pharma-schedules-third-quarter-fiscal-2022-business-update-conference-call https://www.gracetx.com/investors/news-events/press-releases/detail/213/acasti-pharma-to-present-at-the-h-c-wainwright-bioconnect-2022-conference https://www.gracetx.com/investors/news-events/press-releases/detail/212/acasti-pharma-announces-interim-data-meets-all-primary-endpoints-for-pivotal-pk-study-for-gtx-104 https://www.gracetx.com/investors/news-events/press-releases/detail/211/acasti-pharma-ceo-to-participate-in-the-benzinga-all-access-event-on-december-2nd https://www.gracetx.com/investors/news-events/press-releases/detail/210/acasti-pharma-announces-annual-stock-option-grants https://www.gracetx.com/investors/news-events/press-releases/detail/209/acasti-pharma-provides-business-update-for-the-second-quarter-of-fiscal-2022 https://www.gracetx.com/investors/news-events/press-releases/detail/208/acasti-pharma-schedules-second-quarter-fiscal-2022-business-update-conference-call https://www.gracetx.com/investors/news-events/press-releases/detail/207/acasti-pharma-awarded-composition-of-matter-patents-for-gtx-101-in-europe-china-and-mexico-and-for-gtx-102-in-japan https://www.gracetx.com/investors/news-events/press-releases/detail/206/acasti-pharma-announces-initiation-of-pharmacokinetic-bridging-study-for-gtx-104-the-companys-lead-drug-candidate-for-the-treatment-of-subarachnoid-hemorrhage https://www.gracetx.com/investors/news-events/press-releases/detail/205/acasti-pharma-provides-update-following-acquisition-of-grace-therapeutics-and-regains-compliance-with-nasdaq-listing-standards https://www.gracetx.com/investors/news-events/press-releases/detail/204/acasti-pharma-to-present-at-the-oppenheimer-fall-healthcare-summit-on-september-21 https://www.gracetx.com/investors/news-events/press-releases/detail/203/acasti-pharma-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference https://www.gracetx.com/investors/news-events/press-releases/detail/202/acasti-pharma-announces-successful-completion-of-its-merger-with-grace-therapeutics-inc-voting-results-of-its-annual-and-special-meeting-of-shareholders-and-reverse-stock-split https://www.gracetx.com/investors/news-events/press-releases/detail/201/acasti-pharma-provides-business-update-for-the-first-quarter-of-fiscal-2022 https://www.gracetx.com/investors/news-events/press-releases/detail/200/reminder-acasti-pharma-to-host-conference-call-on-august-4th-at-1-00-pm-et-to-discuss-planned-acquisition-of-grace-therapeutics https://www.gracetx.com/investors/news-events/press-releases/detail/199/acasti-pharma-schedules-conference-call-for-august-4th-at-1-00-pm-etto-discuss-planned-acquisition-of-grace-therapeutics https://www.gracetx.com/investors/news-events/press-releases/detail/198/acasti-pharma-provides-fiscal-2021-year-end-business-update https://www.gracetx.com/investors/news-events/press-releases/detail/197/acasti-intends-to-request-hearing-before-nasdaq-panel-to-present-plan-of-compliance https://www.gracetx.com/investors/news-events/press-releases/detail/196/acasti-announces-definitive-agreement-to-acquire-grace-therapeutics-inc https://www.gracetx.com/investors/news-events/press-releases/detail/195/acasti-pharma-provides-update-on-recent-financing-activities https://www.gracetx.com/investors/news-events/press-releases/detail/194/acasti-pharma-announces-results-for-third-quarter-of-fiscal-2021 https://www.gracetx.com/investors/news-events/press-releases/detail/193/acasti-pharma-provides-update-on-recent-financing-activities https://www.gracetx.com/investors/news-events/press-releases/detail/192/acasti-pharma-unaware-of-any-material-change https://www.gracetx.com/investors/news-events/press-releases/detail/191/acasti-pharma-provides-business-update-for-the-second-quarter-of-fiscal-2021 https://www.gracetx.com/investors/news-events/press-releases/detail/190/acasti-pharma-announces-the-election-of-its-directors-advisory-resolution-approving-compensation-amendments-to-its-stock-option-and-equity-incentive-plans-adoption-of-amended-restated-general-by-law-and-other-related-matters-approved-at-its-agm https://www.gracetx.com/investors/news-events/press-releases/detail/189/acasti-announces-review-process-of-strategic-alternatives https://www.gracetx.com/investors/news-events/press-releases/detail/188/acasti-appoints-seasoned-executive-brian-d-ford-cpa-ca-as-chief-financial-officer https://www.gracetx.com/investors/news-events/press-releases/detail/187/acasti-announces-filing-and-mailing-of-information-circular-and-change-in-record-date https://www.gracetx.com/investors/news-events/press-releases/detail/186/acasti-pharma-reports-topline-triglyceride-results-from-phase-3-trilogy-2-study-of-capre-in-patients-with-severe-hypertriglyceridemia https://www.gracetx.com/investors/news-events/press-releases/detail/185/acasti-pharma-provides-business-update-for-the-first-quarter-of-fiscal-2021 https://www.gracetx.com/investors/news-events/press-releases/detail/184/acasti-pharma-submits-statistical-analysis-plan-to-fda-and-remains-on-track-to-report-trilogy-2-topline-data-on-or-about-august-31-2020 https://www.gracetx.com/investors/news-events/press-releases/detail/183/acasti-pharma-provides-fiscal-2020-year-end-business-update https://www.gracetx.com/investors/news-events/press-releases/detail/182/acasti-pharma-receives-fda-response-to-trilogy-1-briefing-package https://www.gracetx.com/investors/news-events/press-releases/detail/181/acasti-pharma-announces-submission-of-trilogy-1-briefing-package-to-fda https://www.gracetx.com/investors/news-events/press-releases/detail/180/acasti-pharma-awarded-notice-of-allowance-for-second-composition-of-matter-patent-in-canada https://www.gracetx.com/investors/news-events/press-releases/detail/179/acasti-pharma-submits-fda-meeting-request-on-schedule-and-fda-meeting-expected-in-the-second-half-of-june https://www.gracetx.com/investors/news-events/press-releases/detail/178/acasti-pharma-awarded-notice-of-allowance-for-additional-composition-of-matter-and-method-of-use-patents-in-the-united-states-and-mexico https://www.gracetx.com/investors/news-events/press-releases/detail/177/acasti-receives-nasdaq-notification-regarding-minimum-bid-requirements https://www.gracetx.com/investors/news-events/press-releases/detail/176/acasti-pharma-provides-business-update-for-the-third-quarter-of-fiscal-2020 https://www.gracetx.com/investors/news-events/press-releases/detail/175/acasti-pharma-schedules-third-quarter-fiscal-2020-andbusiness-update-conference-call https://www.gracetx.com/investors/news-events/press-releases/detail/174/acasti-pharma-provides-update-on-trilogy-1-and-trilogy-2-phase-3-trials-of-capre https://www.gracetx.com/investors/news-events/press-releases/detail/173/acasti-pharma-reports-topline-results-for-trilogy-1-phase-3-trial-of-capre https://www.gracetx.com/investors/news-events/press-releases/detail/172/acasti-pharma-provides-update-on-timing-of-topline-results-for-trilogy-1-phase-3-trial-of-capre https://www.gracetx.com/investors/news-events/press-releases/detail/171/acasti-pharma-reports-last-patient-visit-in-trilogy-1-phase-3-trial-of-capre-for-the-treatment-of-severe-hypertriglyceridemia https://www.gracetx.com/investors/news-events/press-releases/detail/170/acasti-pharma-releases-preliminary-new-animal-data-and-gains-insights-into-capres-novel-mechanism-of-action-in-diabetes https://www.gracetx.com/investors/news-events/press-releases/detail/169/acasti-pharma-provides-business-update-for-the-second-quarter-of-fiscal-2020 https://www.gracetx.com/investors/news-events/press-releases/detail/168/acasti-pharma-announces-publication-of-capre-pharmacokinetics-studyin-a-leading-peer-reviewed-journal https://www.gracetx.com/investors/news-events/press-releases/detail/167/acasti-pharma-schedules-second-quarter-fiscal-2020-conference-call https://www.gracetx.com/investors/news-events/press-releases/detail/166/acasti-pharma-partners-with-aker-biomarine-to-supply-krill-oil-for-capre https://www.gracetx.com/investors/news-events/press-releases/detail/165/acasti-pharma-to-present-at-the-2019-cantor-fitzgerald-global-healthcare-conference https://www.gracetx.com/investors/news-events/press-releases/detail/164/acasti-pharma-announces-additional-phase-3-milestones-reached-and-remains-on-track-to-report-topline-results-for-trilogy-1-in-december-2019-and-trilogy-2-in-january-2020 https://www.gracetx.com/investors/news-events/press-releases/detail/163/acasti-pharma-receives-funding-from-the-government-of-canada-to-expand-production-capacity https://www.gracetx.com/investors/news-events/press-releases/detail/162/acasti-pharma-to-present-at-the-21st-annual-rodman-renshawglobal-investment-conference-in-new-york-city-on-september-9th https://www.gracetx.com/investors/news-events/press-releases/detail/161/acasti-pharma-announces-the-election-of-its-directors-amendments-to-its-stock-option-and-equity-incentive-plans-and-other-related-matters-approved-at-its-agm https://www.gracetx.com/investors/news-events/press-releases/detail/160/acasti-pharma-provides-business-update-for-the-first-quarter-of-fiscal-2020 https://www.gracetx.com/investors/news-events/press-releases/detail/159/acasti-pharma-co-founder-chief-operating-and-scientific-officer-to-participate-on-lipid-panel-at-the-2019-btig-biotechnology-conference https://www.gracetx.com/investors/news-events/press-releases/detail/158/acasti-pharma-schedules-first-quarter-fiscal-2020-conference-call https://www.gracetx.com/investors/news-events/press-releases/detail/157/acasti-pharma-comments-on-trading-activity-and-reaffirms-no-plans-to-raise-capital https://www.gracetx.com/investors/news-events/press-releases/detail/156/acasti-pharma-provides-fiscal-2019-year-end-business-update https://www.gracetx.com/investors/news-events/press-releases/detail/155/acasti-pharma-awarded-notice-of-allowance-for-a-second-patent-in-china-covering-capres-omega-3-phospholipid-composition https://www.gracetx.com/investors/news-events/press-releases/detail/154/acasti-pharma-schedules-fourth-quarter-and-fiscal-2019-conference-call https://www.gracetx.com/investors/news-events/press-releases/detail/153/acasti-pharma-announces-trilogy-2-trial-has-achieved-its-100-patient-randomization-target-in-patients-with-severe-hypertriglyceridemia https://www.gracetx.com/investors/news-events/press-releases/detail/152/acasti-issues-shares-in-settlement-of-claims-with-former-chief-executive-officer https://www.gracetx.com/investors/news-events/press-releases/detail/151/acasti-pharma-to-present-at-the-20th-annual-b-riley-fbr-institutional-investor-conference https://www.gracetx.com/investors/news-events/press-releases/detail/150/acasti-pharma-awarded-notices-of-allowance-for-additional-composition-use-patents-in-mexico-chile-and-israel https://www.gracetx.com/investors/news-events/press-releases/detail/149/acasti-settles-claims-with-former-chief-executive-officer https://www.gracetx.com/investors/news-events/press-releases/detail/148/acasti-pharma-ceo-to-present-at-the-thinkequity-conference-on-may-2nd-in-new-york-city https://www.gracetx.com/investors/news-events/press-releases/detail/147/acasti-pharma-announces-trilogy-1-trial-has-achieved-100-patient-randomization-in-patients-with-severe-hypertriglyceridemia https://www.gracetx.com/investors/news-events/press-releases/detail/146/acasti-pharma-announces-publication-of-capre-bioavailability-study-in-leading-peer-reviewed-journal https://www.gracetx.com/investors/news-events/press-releases/detail/145/acasti-pharma-to-present-at-the-2019-spring-investor-summit-in-new-york-city-on-april-2nd https://www.gracetx.com/investors/news-events/press-releases/detail/144/acasti-pharma-to-present-at-the-oppenheimer-29th-annual-healthcare-conference-on-march-19th https://www.gracetx.com/investors/news-events/press-releases/detail/143/acasti-pharma-recognized-in-tsx-venture-exchanges-2019-venture-50 https://www.gracetx.com/investors/news-events/press-releases/detail/142/acasti-pharma-provides-business-update-for-the-third-quarter-of-fiscal-2019 https://www.gracetx.com/investors/news-events/press-releases/detail/141/acasti-pharma-schedules-third-quarter-fiscal-2019-conference-call https://www.gracetx.com/investors/news-events/press-releases/detail/5/acasti-pharma-awarded-broad-composition-of-matter-and-method-of-use-patents-by-the-european-patent-office https://www.gracetx.com/investors/news-events/press-releases/detail/120/acasti-pharma-announces-trilogy-phase-3-trials-of-capre-in-patients-with-severe-hypertriglyceridemia-has-now-exceeded-65-randomization-and-more-than-100-patients-20-have-completed-their-6-month-treatment-plan https://www.gracetx.com/investors/news-events/press-releases/detail/119/acasti-pharma-achieves-planned-enrollment-targets-for-trilogy-phase-3-trials-of-capre-in-patients-with-severe-hypertriglyceridemia https://www.gracetx.com/investors/news-events/press-releases/detail/118/acasti-pharma-provides-business-update-for-second-quarter-of-fiscal-2019 https://www.gracetx.com/investors/news-events/press-releases/detail/117/acasti-pharma-schedules-second-quarter-fiscal-2019-conference-call https://www.gracetx.com/investors/news-events/press-releases/detail/116/acasti-pharma-announces-closing-of-19-1-million-underwritten-public-offering-of-common-shares https://www.gracetx.com/investors/news-events/press-releases/detail/115/acasti-pharma-announces-pricing-of-16-6-million-underwritten-public-offering-of-common-shares https://www.gracetx.com/investors/news-events/press-releases/detail/114/acasti-pharma-announces-proposed-underwritten-public-offering-of-common-shares https://www.gracetx.com/investors/news-events/press-releases/detail/113/acasti-pharma-announces-issuance-of-common-shares-in-payment-of-outstanding-interest-under-debentures https://www.gracetx.com/investors/news-events/press-releases/detail/112/acasti-pharma-appoints-jean-franois-boily-as-vice-president-of-finance https://www.gracetx.com/investors/news-events/press-releases/detail/111/acasti-pharma-provides-clinical-and-market-update https://www.gracetx.com/investors/news-events/press-releases/detail/110/acasti-pharma-announces-the-election-of-its-directors-changes-to-its-stock-option-plan-and-other-related-matters-approved-at-its-agm https://www.gracetx.com/investors/news-events/press-releases/detail/109/acasti-pharma-provides-business-update-for-the-first-quarter-of-fiscal-2019 https://www.gracetx.com/investors/news-events/press-releases/detail/108/acasti-pharma-announces-mailing-of-management-information-circularand-amendment-to-stock-option-plan https://www.gracetx.com/investors/news-events/press-releases/detail/107/acasti-pharma-awarded-composition-of-matter-patentby-the-u-s-patent-and-trademark-office https://www.gracetx.com/investors/news-events/press-releases/detail/106/acasti-pharma-announces-annual-performance-grants-of-stock-options-amendment-of-stock-option-plan-and-issuance-of-common-shares-in-payment-of-outstanding-interest-under-debentures https://www.gracetx.com/investors/news-events/press-releases/detail/105/acasti-pharma-business-update-for-the-fourth-quarter-and-fiscal-2018 https://www.gracetx.com/investors/news-events/press-releases/detail/104/acasti-pharma-reports-on-positive-feedback-following-todays-presentation-at-the-xviii-international-symposium-on-atherosclerosis https://www.gracetx.com/investors/news-events/press-releases/detail/103/acasti-pharma-to-present-at-the-xviiith-international-symposium-on-atherosclerosis https://www.gracetx.com/investors/news-events/press-releases/detail/102/acasti-pharma-appoints-brian-groch-as-chief-commercial-officer https://www.gracetx.com/investors/news-events/press-releases/detail/101/acasti-pharma-retains-crescendo-communications-for-investor-relations-services-in-the-united-states https://www.gracetx.com/investors/news-events/press-releases/detail/100/acasti-pharma-appoints-donald-olds-to-its-board-of-directors-and-audit-committee https://www.gracetx.com/investors/news-events/press-releases/detail/99/acasti-pharma-announces-issuance-of-common-shares-in-payment-of-outstanding-interest-under-debentures https://www.gracetx.com/investors/news-events/press-releases/detail/98/acasti-pharma-announces-first-patient-randomized-in-pivotal-trilogy-phase-3-program-of-capre-in-severe-hypertriglyceridemia https://www.gracetx.com/investors/news-events/press-releases/detail/97/acasti-pharma-reports-third-quarter-fy-2018-financial-results https://www.gracetx.com/investors/news-events/press-releases/detail/96/acasti-pharma-announces-the-closing-of-over-allotment-option-for-its-public-offering-of-common-shares https://www.gracetx.com/investors/news-events/press-releases/detail/95/acasti-pharma-announces-change-to-board-of-directors https://www.gracetx.com/investors/news-events/press-releases/detail/94/acasti-pharma-announces-issuance-of-common-shares-in-payment-of-outstanding-interest-under-debentures https://www.gracetx.com/investors/news-events/press-releases/detail/93/acasti-expands-global-patent-portfolio-with-newly-granted-patents-in-south-korea-and-canada https://www.gracetx.com/investors/news-events/press-releases/detail/92/acasti-pharma-to-present-at-biotech-showcase-conference https://www.gracetx.com/investors/news-events/press-releases/detail/91/acasti-pharma-announces-closing-of-us10-million-firm-commitment-offering-of-common-shares-and-warrants https://www.gracetx.com/investors/news-events/press-releases/detail/90/acasti-pharma-announces-pricing-of-us10-million-offering-of-common-shares-and-warrants https://www.gracetx.com/investors/news-events/press-releases/detail/89/acasti-pharma-clarifies-term-of-proposed-strategic-partnership-with-leading-china-pharmaceutical-company https://www.gracetx.com/investors/news-events/press-releases/detail/88/acasti-pharma-announces-development-and-commercialization-discussions-progressing-with-a-leading-china-pharmaceutical-partner https://www.gracetx.com/investors/news-events/press-releases/detail/87/acasti-pharma-reports-second-quarter-fy-2018-financial-results https://www.gracetx.com/investors/news-events/press-releases/detail/86/acasti-pharma-announces-dariush-mozaffarian-m-d-dr-p-h-principal-investigator-for-capre-phase-3-development-program https://www.gracetx.com/investors/news-events/press-releases/detail/85/acasti-pharma-announces-issuance-of-common-shares-in-payment-of-outstanding-interest-under-debentures https://www.gracetx.com/investors/news-events/press-releases/detail/84/acasti-pharma-grants-stock-options https://www.gracetx.com/investors/news-events/press-releases/detail/83/acasti-pharma-announces-the-election-of-its-directors-changes-to-its-stock-option-plan-and-other-related-matters-approved-at-its-agm https://www.gracetx.com/investors/news-events/press-releases/detail/82/acasti-pharma-reports-first-quarter-fy-2018-financial-results https://www.gracetx.com/investors/news-events/press-releases/detail/81/acasti-pharma-announces-issuance-of-common-shares-in-payment-of-outstanding-interest-under-debentures https://www.gracetx.com/investors/news-events/press-releases/detail/80/correction-acasti-pharma-grants-stock-options https://www.gracetx.com/investors/news-events/press-releases/detail/79/acasti-pharma-grants-stock-options https://www.gracetx.com/investors/news-events/press-releases/detail/78/acasti-pharma-to-present-at-upcoming-international-industry-conferences https://www.gracetx.com/investors/news-events/press-releases/detail/77/acasti-pharma-reports-fourth-quarter-and-full-year-2017-financial-results https://www.gracetx.com/investors/news-events/press-releases/detail/76/acasti-pharma-presents-capre-clinical-data-at-national-lipid-association-scientific-sessions https://www.gracetx.com/investors/news-events/press-releases/detail/75/acasti-granted-additional-composition-use-patents-in-taiwan-and-australia-safeguards-valuable-market-expansion-opportunities https://www.gracetx.com/investors/news-events/press-releases/detail/74/acasti-pharma-to-present-capre-omega-3-bridging-study-results-at-national-lipid-association-scientific-sessions https://www.gracetx.com/investors/news-events/press-releases/detail/73/acasti-pharma-provides-update-on-capre-phase-3-development-program https://www.gracetx.com/investors/news-events/press-releases/detail/72/acasti-pharma-forms-scientific-advisory-board-and-appoints-two-leading-cardiovascular-disease-experts https://www.gracetx.com/investors/news-events/press-releases/detail/71/acasti-pharma-grants-incentive-stock-and-options https://www.gracetx.com/investors/news-events/press-releases/detail/70/acasti-pharma-announces-proposed-private-placement-of-convertible-debentures-and-amended-proposed-offering-of-units https://www.gracetx.com/investors/news-events/press-releases/detail/69/acasti-pharma-reports-third-quarter-2017-financial-results https://www.gracetx.com/investors/news-events/press-releases/detail/68/acasti-pharma-appoints-linda-okeefe-as-chief-financial-officer https://www.gracetx.com/investors/news-events/press-releases/detail/67/acasti-announces-stock-ticker-symbol-change-to-acst-on-the-tsxv https://www.gracetx.com/investors/news-events/press-releases/detail/66/acasti-pharma-builds-intellectual-property-portfolio-with-newly-issued-u-s-patent-for-capre https://www.gracetx.com/investors/news-events/press-releases/detail/65/acasti-pharma-reports-second-quarter-2017-financial-results https://www.gracetx.com/investors/news-events/press-releases/detail/64/acasti-pharma-reports-positive-capre-omega-3-bridging-study-data https://www.gracetx.com/investors/news-events/press-releases/detail/63/acasti-announces-the-election-of-its-directors-change-of-fiscal-year-end-and-other-related-matters-passed-at-its-agm https://www.gracetx.com/investors/news-events/press-releases/detail/62/acasti-announces-first-quarter-results https://www.gracetx.com/investors/news-events/press-releases/detail/61/acasti-announces-grant-of-stock-options https://www.gracetx.com/investors/news-events/press-releases/detail/60/acasti-announces-fourth-quarter-and-fiscal-year-results https://www.gracetx.com/investors/news-events/press-releases/detail/59/jan-dalvise-appointed-president-ceo-of-acasti-pharma https://www.gracetx.com/investors/news-events/press-releases/detail/58/nasdaq-grants-acasti-cure-period-to-regain-compliance-with-audit-committee-membership-requirements https://www.gracetx.com/investors/news-events/press-releases/detail/57/acasti-announces-management-appointment-and-changes-to-the-board-of-directors https://www.gracetx.com/investors/news-events/press-releases/detail/56/acasti-announces-share-for-debt https://www.gracetx.com/investors/news-events/press-releases/detail/55/acasti-announces-third-quarter-results https://www.gracetx.com/investors/news-events/press-releases/detail/54/acasti-neptune-enter-into-transactional-arrangement-sign-operational-agreements https://www.gracetx.com/investors/news-events/press-releases/detail/53/acasti-provides-update-on-capre-development-pathway https://www.gracetx.com/investors/news-events/press-releases/detail/52/acasti-granted-composition-use-patent-in-japan-taiwan-and-mexico https://www.gracetx.com/investors/news-events/press-releases/detail/51/acasti-announces-second-quarter-results https://www.gracetx.com/investors/news-events/press-releases/detail/50/acasti-announces-1-for-10-reverse-stock-split https://www.gracetx.com/investors/news-events/press-releases/detail/49/acasti-announces-grant-of-stock-options https://www.gracetx.com/investors/news-events/press-releases/detail/48/acasti-announces-first-quarter-results https://www.gracetx.com/investors/news-events/press-releases/detail/47/acasti-announces-grant-of-stock-options https://www.gracetx.com/investors/news-events/press-releases/detail/46/acasti-announces-fourth-quarter-and-fiscal-year-results https://www.gracetx.com/investors/news-events/press-releases/detail/45/acasti-announces-new-board-of-director-nominees-for-election-at-annual-and-special-meeting-of-shareholders https://www.gracetx.com/investors/news-events/press-releases/detail/44/acasti-receives-extension-to-regain-compliance-with-nasdaq-minimum-bid-price-rule https://www.gracetx.com/investors/news-events/press-releases/detail/43/acasti-announces-departure-of-chief-financial-officer https://www.gracetx.com/investors/news-events/press-releases/detail/41/acasti-granted-composition-use-patent-in-china https://www.gracetx.com/investors/news-events/press-releases/detail/42/acasti-receives-full-data-for-phase-ii-trifecta-trial https://www.gracetx.com/investors/news-events/press-releases/detail/40/acasti-announces-third-quarter-results https://www.gracetx.com/investors/news-events/press-releases/detail/39/acasti-receives-nasdaq-notification-regarding-minimum-bid-requirements https://www.gracetx.com/investors/news-events/press-releases/detail/37/acasti-announces-grant-of-stock-options https://www.gracetx.com/investors/news-events/press-releases/detail/38/acasti-announces-second-quarter-results https://www.gracetx.com/investors/news-events/press-releases/detail/36/acasti-announces-positive-top-line-pharmacokinetic-results https://www.gracetx.com/investors/news-events/press-releases/detail/35/acasti-reports-successful-caprer-phase-ii-trifecta-results-proving-statistically-significant-improvements-in-triglycerides-non-hdl-c https://www.gracetx.com/investors/news-events/press-releases/detail/32/acasti-announces-oral-presentation-on-colt-study-results-at-19th-world-congress-on-heart-disease-in-boston https://www.gracetx.com/investors/news-events/press-releases/detail/34/acasti-announces-first-quarter-results https://www.gracetx.com/investors/news-events/press-releases/detail/33/acasti-completes-phase-ii-double-blind-trifecta-and-pharmacokinetic-trials https://www.gracetx.com/investors/news-events/press-releases/detail/31/acasti-grants-of-stock-options-to-newly-appointed-board-members https://www.gracetx.com/investors/news-events/press-releases/detail/29/acasti-reports-results-of-annual-and-special-meeting https://www.gracetx.com/investors/news-events/press-releases/detail/30/acasti-announces-resignation-of-chief-financial-officer https://www.gracetx.com/investors/news-events/press-releases/detail/27/acasti-announces-fourth-quarter-and-fiscal-year-results https://www.gracetx.com/investors/news-events/press-releases/detail/28/acasti-to-present-at-two-scientific-forums https://www.gracetx.com/investors/news-events/press-releases/detail/26/acasti-announces-closing-of-cad2-15-million-private-placement https://www.gracetx.com/investors/news-events/press-releases/detail/24/acasti-announces-third-quarter-results https://www.gracetx.com/investors/news-events/press-releases/detail/25/fda-clears-acastis-investigational-new-drug-submission-to-conduct-pk-trial https://www.gracetx.com/investors/news-events/press-releases/detail/21/acasti-appoints-jerald-j-wenker-as-special-advisor-and-nominee-to-its-board-of-directors https://www.gracetx.com/investors/news-events/press-releases/detail/20/neptune-acasti-and-enzymotec-sign-settlement-term-sheet-resulting-in-stay-of-itc-investigation-for-30-days https://www.gracetx.com/investors/news-events/press-releases/detail/22/neptune-and-aker-biomarine-reach-patent-infringement-settlement-and-license-agreement https://www.gracetx.com/investors/news-events/press-releases/detail/23/acasti-announces-closing-of-us23-million-underwritten-offering-of-units https://www.gracetx.com/investors/news-events/press-releases/detail/19/acasti-announces-pricing-of-us20-million-offering-of-units https://www.gracetx.com/investors/news-events/press-releases/detail/18/acasti-announces-proposed-offering-of-units https://www.gracetx.com/investors/news-events/press-releases/detail/16/acasti-completes-pk-ind-submission https://www.gracetx.com/investors/news-events/press-releases/detail/17/reed-v-tuckson-m-d-joins-acastis-board-of-directors https://www.gracetx.com/investors/news-events/press-releases/detail/14/acasti-strengthens-its-ip-portfolio https://www.gracetx.com/investors/news-events/press-releases/detail/15/acasti-announces-second-quarter-results https://www.gracetx.com/investors/news-events/press-releases/detail/13/acasti-announces-positive-phase-ii-open-label-clinical-trial-results https://www.gracetx.com/investors/news-events/press-releases/detail/7/acasti-signs-manufacturing-agreement https://www.gracetx.com/investors/news-events/press-releases/detail/6/acasti-announces-first-quarter-results https://www.gracetx.com/investors/news-events/press-releases/detail/8/acasti-reports-results-of-annual-and-special-meeting https://www.gracetx.com/investors/news-events/press-releases/detail/11/acasti-announces-fiscal-2013-results-and-provides-update-on-status-of-clinical-trials https://www.gracetx.com/investors/news-events/press-releases/detail/12/acasti-pharma-presents-preliminary-data-moving-forward-with-clinical-strategy https://www.gracetx.com/investors/news-events/press-releases/detail/9/acasti-pharma-reports-its-third-quarter-results https://www.gracetx.com/investors/news-events/press-releases/detail/10/acasti-pharma-shares-to-trade-on-nasdaq https://www.gracetx.com/investors/news-events/press-releases/detail/140/acasti-pharma-provides-an-insight-of-its-current-clinical-trials-results https://www.gracetx.com/investors/news-events/press-releases/detail/139/acasti-pharma-becomes-royalty-free https://www.gracetx.com/investors/news-events/press-releases/detail/138/acasti-pharma-provides-update-after-explosion-at-neptunes-plant https://www.gracetx.com/investors/news-events/press-releases/detail/137/acasti-pharma-first-quarter-results https://www.gracetx.com/investors/news-events/press-releases/detail/136/acasti-pharma-to-present-at-jmp-securities-healthcare-conference https://www.gracetx.com/investors/news-events/press-releases/detail/135/acasti-pharma-announces-year-end-results-and-corporate-reorganization https://www.gracetx.com/investors/news-events/press-releases/detail/134/acasti-to-present-at-the-annual-roth-conference-and-grants-incentive-stock-options https://www.gracetx.com/investors/news-events/press-releases/detail/133/acasti-pharma-closes-2000000-cdn-private-placement https://www.gracetx.com/investors/news-events/press-releases/detail/132/acasti-pharma-announces-a-private-placement-financing-of-approximately-2000000-cdn https://www.gracetx.com/investors/news-events/press-releases/detail/131/acasti-pharma-reports-third-quarter-results https://www.gracetx.com/investors/news-events/press-releases/detail/130/acasti-pharma-to-present-at-onemedforum-conference https://www.gracetx.com/investors/news-events/press-releases/detail/129/acasti-pharma-to-present-at-the-american-academy-of-anti-aging-medicine-a4m-and-to-the-american-academy-of-private-physicians https://www.gracetx.com/investors/news-events/press-releases/detail/128/acasti-pharma-announces-the-initiation-of-a-second-phase-ii-clinical-study-and-consolidation-of-its-ip-position https://www.gracetx.com/investors/news-events/press-releases/detail/127/acasti-pharma-inc-receives-health-canada-clearance-for-an-open-label-phase-ii-hypertriglyceridemia-trial https://www.gracetx.com/investors/news-events/press-releases/detail/126/acasti-pharma-reports-second-quarter-results https://www.gracetx.com/investors/news-events/press-releases/detail/125/acasti-pharma-announces-the-initiation-of-phase-ii-clinical-study-of-caprer-for-the-treatment-of-hypertriglyceridemia https://www.gracetx.com/investors/news-events/press-releases/detail/124/acasti-pharma-to-present-at-jmp-healthcare-conference https://www.gracetx.com/investors/news-events/press-releases/detail/123/acasti-pharma-reports-on-its-oversubscribed-rights-offering https://www.gracetx.com/investors/news-events/press-releases/detail/122/acasti-pharma-reports-first-quarter-results https://www.gracetx.com/investors/news-events/press-releases/detail/121/acasti-pharma-inc-to-welcome-dr-harlan-waksal https://www.gracetx.com/privacy-policy https://www.gracetx.com/disclaimer https://www.gracetx.com/sitemap https://www.gracetx.com/accessibility-statement